How should kratom withdrawal be managed in an adult patient who has stopped regular use and presents with anxiety, irritability, insomnia, myalgia, nausea, vomiting, diarrhea, and diaphoresis?

Kratom Withdrawal Management

Manage kratom withdrawal with symptom-directed supportive care using clonidine (0.1-0.2 mg every 6 hours as needed), hydroxyzine (25-50 mg every 6 hours), gabapentin (300-600 mg three times daily), loperamide for diarrhea, and antiemetics for nausea—the same approach used for opioid withdrawal—with consideration of buprenorphine-naloxone for severe cases or maintenance therapy.

Clinical Recognition and Assessment

Kratom withdrawal presents identically to opioid withdrawal with both psychological symptoms (anxiety, irritability, restlessness, depressed mood, insomnia) and physical symptoms (myalgia, joint pain, diaphoresis, lacrimation, rhinorrhea, diarrhea, nausea, vomiting, tremors, chills, and feverish sensations) 1. The Clinical Opiate Withdrawal Scale (COWS) can quantify severity, with scores >30 indicating severe withdrawal 2.

Critical pitfall: Standard urine toxicology does not detect kratom alkaloids. Diagnosis relies entirely on history and clinical presentation 2. Patients may not volunteer kratom use because they perceive it as "natural" or legal, so direct questioning is essential.

Emerging High-Potency Derivatives

Be aware that newer semisynthetic kratom products, particularly mitragynine pseudoindoxyl (MP) and concentrated 7-hydroxymitragynine (7-OH), produce more severe, rapid-onset withdrawal than traditional powdered kratom 2, 3. These derivatives act as potent μ-opioid receptor agonists and can cause withdrawal symptoms within hours of last use, similar to short-acting opioids 2.

First-Line Symptomatic Management

The primary approach mirrors opioid withdrawal treatment using nonopioid medications 4:

α2-Adrenergic Agonists

• Clonidine is the cornerstone: 0.1-0.2 mg every 6 hours as needed for autonomic symptoms
• Monitor blood pressure before each dose; hold if systolic BP <90 mmHg or symptomatic hypotension
• Successfully used in multiple kratom withdrawal cases 2, 5

Adjunctive Medications

• Hydroxyzine 25-50 mg every 6 hours for anxiety and restlessness 2, 5
• Gabapentin 300-600 mg three times daily for myalgia, anxiety, and insomnia 2
• Loperamide for diarrhea (standard dosing) 4
• Antiemetics (ondansetron or promethazine) for nausea/vomiting 4, 2
• Benzodiazepines can be considered for severe anxiety or muscle cramps, though not routinely necessary 4

This regimen typically resolves symptoms within 72-96 hours 2.

Opioid Agonist Therapy Considerations

Buprenorphine-Naloxone (Suboxone)

Buprenorphine-naloxone is the most evidence-supported medication for kratom use disorder, particularly for patients with severe dependence, failed outpatient management, or need for maintenance therapy 1, 6.

Critical timing consideration: Unlike traditional opioid withdrawal, buprenorphine can sometimes be initiated without precipitating severe withdrawal in kratom users, as demonstrated by successful naltrexone administration without precipitation 2. However, cases of precipitated withdrawal have occurred 3, so:

• Wait until moderate withdrawal symptoms appear (COWS ≥8-12)
• Start with low doses (2-4 mg sublingual)
• Titrate based on response

Buprenorphine is particularly valuable for:

• Long-term maintenance to prevent relapse 1, 7
• Pregnant patients with kratom use disorder 6
• Patients transitioning from high-potency derivatives 2

Methadone

Recent evidence shows methadone (mean dose ~100 mg, range 35-190 mg) is highly effective for kratom use disorder in opioid treatment program settings, with 93% retention rates 8. However, outpatient methadone requires enrollment in a licensed opioid treatment program. Emergency departments can administer (but not prescribe) methadone for up to 72 hours while arranging referral 4.

Treatment Duration and Relapse Prevention

Acute withdrawal symptoms resolve in 3-5 days, but psychological symptoms (craving, anxiety, mood disturbance, insomnia) can persist for weeks to months 9, 1. This protracted withdrawal phase significantly increases relapse risk 7.

For maintenance therapy:

• Buprenorphine-naloxone should be continued long-term (months to years) 1, 7
• Naltrexone (including long-acting injectable Vivitrol) can be initiated after establishing an opioid-free interval and may prevent relapse 2
• One case report suggests clomipramine (tricyclic antidepressant) may help persistent mood and anxiety symptoms after withdrawal 9, though this requires further validation

Special Populations

Pregnant patients: Buprenorphine is the preferred treatment for kratom use disorder in pregnancy, with dosing similar to opioid use disorder management 6. Neonatal withdrawal symptoms (irritability, feeding intolerance, vomiting) have been reported with maternal kratom use 1.

Patients with polysubstance use: Concurrent nicotine pouch or other substance withdrawal can complicate the clinical picture and may require intensive care for severe cases 3.

Disposition Algorithm

• Mild withdrawal (COWS <13): Outpatient management with symptom-directed medications and close follow-up
• Moderate withdrawal (COWS 13-24): Consider observation unit or brief admission; initiate buprenorphine if appropriate
• Severe withdrawal (COWS >24) or failed outpatient management: Inpatient admission; strongly consider buprenorphine or methadone 2, 3
• All patients: Arrange addiction medicine follow-up and provide harm reduction counseling

The evidence consistently demonstrates that kratom withdrawal, while rarely life-threatening, causes significant morbidity and high relapse rates without appropriate management and follow-up 1, 7.